Influence of immunotherapy with interferon-α on regulatory T cells in renal cell carcinoma patients

Journal of Interferon and Cytokine Research

Volumn 30, Issue 1, 2010, Pages 43-47

  Tatsugami, Katsunori ^a   Eto, Masatoshi ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; MONOTHERAPY; NEPHRECTOMY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

AGED; ANTIGENS, CD; CARCINOMA, RENAL CELL; CELL COUNT; DISEASE PROGRESSION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 75149158389     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2009.0014     Document Type: Article

References (25)

1. Atkins MB. 2002. Interleukin-2: clinical applications. Semin Oncol 29:12-17.
2. Beadling C, Smith KA. 2002. DNA array analysis of interleukin-2- regulated immediate/early genes. Med Immunol 1:2.
3. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. 2002. Interferonalpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119-134.
4. Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, Cha TL, Sun GH. 2008. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 99:905-913.
5. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949.
6. Ferrantini M, Belardelli F. 2000. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin Cancer Biol 10:145-157.
7. Fragale A, Gabriele L, Stellacci E, Borghi P, Perrotti E, Ilari R, Lanciotti A, Remoli AL, Venditti M, Belardelli F, Battistini A. 2008. IFN regulatory factor-1 negatively regulates CD4+ CD25+ regulatory T cell differentiation by repressing Foxp3 expression. J Immunol 181:1673-1682.
8. Gigante M, Mandic M, Wesa AK, Cavalcanti E, Dambrosio M, Mancini V, Battaglia M, Gesualdo L, Storkus WJ, Ranieri E. 2008. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother 31:254-262.
9. Isaacs A, Lindenmann J. 1957. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147:258-267.
10. Ito N, Eto M, Nakamura E, Takahashi A, Tsukamoto T, Toma H, Nakazawa H, Hirao Y, Uemura H, Kagawa S, Kanayama H, Nose Y, Kinukawa N, Nakamura T, Jinnai N, Seki T, Takamatsu M, Masui Y, Naito S, Ogawa O. 2007. STAT3 polymorphism predicts interferon-alpha response in patients with metastatic renal cell carcinoma. J Clin Oncol 25:2785-2791.
11. Jonasch E, Haluska FG. 2001. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6:34-55.
12. Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T, Matikainen S. 2003. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine 24:81-90.
13. Luft T, Luetjens P, Hochrein H, Toy T, Masterman KA, Rizkalla M, Maliszewski C, Shortman K, Cebon J, Maraskovsky E. 2002. IFNalpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol 14:367-380.
14. Malek TR, Bayer AL. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4:665-674.
15. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128-3133.
16. Padovan E, Spagnoli GC, Ferrantini M, Heberer M. 2002. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocytederived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol 71:669-676.
17. Piemonti L, Monti P, Allavena P, Sironi M, Soldini L, Leone BE, Socci C, Di Carlo V. 1999. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 162:6473-6481.
18. Ramsey S, Lamb GW, Aitchison M, McMillan DC. 2006. The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br J Cancer 95:1076-1080.
19. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. 2005. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201:723-735.
20. Shevach EM. 2001. Certifi ed professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 193:F41-F46.
21. Shimizu J, Yamazaki S, Sakaguchi S. 1999. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211-5218.
22. Tatsugami K, Eto M, Harano M, Nagafuji K, Omoto K, Katano M, Harada M, Naito S. 2004. Dendritic-cell therapy after nonmyeloablative stem-cell transplantation for renal-cell carcinoma. Lancet Oncol 5:750-752.
23. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. 2005. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23:307-336.
24. Valencia X, Yarboro C, Illei G, Lipsky PE. 2007. Deficient CD4+ CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 178:2579-2588.
25. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC, Berzofsky JA, Carter CS, Read EJ, Helman LJ, Mackall CL. 2005. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+ CD25+ regulatory T cells. Nat Med 11:1238-1243.